Clinical Trial Update: Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a three-drug combination of azacitidine, venetoclax, and pevonedistat in newly diagnosed acute myeloid leukemia. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Atypical Chronic Myeloid Leukemia Bcr-abl1 Negative

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Pevonedistat (pevonedistat)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING